Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors

G. Caocci, O. Mulas, M. Annunziata, L. Luciano, E. Abruzzese, M. Bonifacio, E.M. Orlandi, F. Albano, S. Galimberti, A. Iurlo, P. Pregno, N. Sgherza, B. Martino, G. Binotto, F. Castagnetti, A. Gozzini, M. Bocchia, C. Fozza, F. Stagno, M.P. SimulaF. De Gregorio, M.M. Trawinska, L. Scaffidi, C. Elena, I. Attolico, C. Baratè, D. Cattaneo, F. Pirillo, G. Gugliotta, A. Sicuranza, M. Molica, G. La Nasa, R. Foà, M. Breccia

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Limited information is available regarding the rate of long-term cardiovascular (CV) mortality in chronic myeloid leukaemia (CML) patients treated with second- and third-generation tyrosine kinase inhibitors (2ndG/3rdG TKIs) in the real-life practice. Methods: We identified 656 consecutive CML patients treated with nilotinib, dasatinib, bosutinib and ponatinib. Results: The 15-year CV-mortality free survival was 93 ± 2.8%. Age ≥65 years (p = 0.005) and a positive history of CV disease (p = 0.04) were significantly associated with a lower CV-mortality free survival. CV disease accounted for 16.5% and 5% of potential years of life lost (PYLL) in male and female patients, respectively. The standard mortality ratio (SMR) following ischemic heart disease (IHD) was 3.9 in males and 3.8 in female patients, meaning an excess of IHD deaths observed, in comparison with the population of control. Conclusion. Prevention strategies based on CV risk factors, in particular in those patients with a previous history of CV disease, should be considered.

Original languageEnglish
Pages (from-to)163-166
Number of pages4
JournalInternational Journal of Cardiology
Volume301
DOIs
Publication statusPublished - 2020

Keywords

  • a
  • Cardiovascular toxicity
  • Chronic myeloid leuk
  • emia
  • Ischemic heart disease
  • TKI
  • bosutinib
  • dasatinib
  • nilotinib
  • ponatinib
  • adult
  • age distribution
  • aged
  • Article
  • body mass
  • cancer growth
  • cardiovascular disease
  • cardiovascular mortality
  • cardiovascular risk
  • chronic myeloid leukemia
  • cohort analysis
  • comorbidity
  • diabetes mellitus
  • epidemiological data
  • female
  • human
  • incidence
  • ischemic heart disease
  • Italian (citizen)
  • kidney failure
  • major clinical study
  • male
  • medical history
  • mortality rate
  • preventive medicine
  • primary health care
  • priority journal
  • retrospective study
  • risk factor
  • secondary health care
  • sex difference
  • smoking habit
  • standardized mortality ratio
  • survival rate
  • systolic blood pressure
  • total cholesterol level
  • very elderly

Fingerprint

Dive into the research topics of 'Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors'. Together they form a unique fingerprint.

Cite this